title: Pancreaticojejunostomy versus controlled pancreaticocutaneous fistula in pancreaticoduodenectomy for periampullary carcinoma.
abstract: BACKGROUND
  Anastomotic leak of the pancreaticojejunostomy is a major cause of morbidity and mortality following pancreaticoduodenectomy. Reports have described a large variety of techniques for performing this anastomosis and managing the pancreatic stump. In an attempt to obviate the pancreaticojejunostomy, we prospectively studied the technique of ligating the pancreatic duct and using external drains to create a temporary controlled pancreaticocutaneous fistula.
  
  
  METHODS
  Thirty-five consecutive patients who were to undergo pancreaticoduodenectomy for periampullary carcinoma were prospectively randomized to one of two groups: pancreaticojejunostomy (PJ) (n = 18) or controlled pancreaticocutaneous fistula (CPF) (n = 17). The groups were well matched for age, sex, coexisting medical illnesses, type of tumor, and preoperative condition. Except for the management of the pancreatic remnant, all patients in both groups underwent an identical procedure. Major morbidity, length of hospitalization, duration of the controlled pancreatic fistula, and mortality were analyzed over a mean follow-up interval of 26 months (range 5 months to 7.5 years).
  
  
  RESULTS
  The CPF group experienced lower overall operative morbidity rates than the PJ group (24% versus 56%, P < 0.01). Two patients (11%) in the PJ group and none in the CPF group died (P = NS). Half the morbidity in the PJ group and both mortalities were related to anastomotic leak. The CPF and PJ groups left the hospital after mean stays of 26.4 and 42.2 days respectively (< 0.01).
  
  
  CONCLUSIONS
  Compared to pancreaticojejunal anastomosis, creation of a temporary controlled pancreaticocutaneous fistula in patients who undergo pancreaticoduodenectomy for periampullary malignancy has no appreciable risk. It is associated with reduced morbidity and shorter length of hospitalization.
authors.affiliation: Department of General Surgery, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: P
authors.initials: P
authors.lastname: Reissman
authors.forename: Y
authors.initials: Y
authors.lastname: Perry
authors.forename: A
authors.initials: A
authors.lastname: Cuenca
authors.forename: A
authors.initials: A
authors.lastname: Bloom
authors.forename: A
authors.initials: A
authors.lastname: Eid
authors.forename: E
authors.initials: E
authors.lastname: Shiloni
authors.forename: A
authors.initials: A
authors.lastname: Rivkind
authors.forename: A
authors.initials: A
authors.lastname: Durst
mesh_terms: D000328:Adult; D000368:Aged; D014670:Ampulla of Vater; D000714:Anastomosis, Surgical / Q000009:adverse effects / Q000379:methods; D003138:Common Bile Duct Neoplasms / Q000401:mortality / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007902:Length of Stay; D008026:Ligation / Q000379:methods; D008297:Male; D008875:Middle Aged; D010183:Pancreatic Ducts / Q000601:surgery; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000601:surgery*; D016577:Pancreaticoduodenectomy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D010193:Pancreaticojejunostomy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D011183:Postoperative Complications; D011446:Prospective Studies; D012086:Reoperation; D015996:Survival Rate